Chronotherapy for rheumatoid arthritis: current perspectives

Hideto To
Department of Medical Pharmaceutics, Graduate School of Medicine and Pharmaceutical Sciences for Research, University of Toyama, Toyama, Japan

Abstract: Rheumatoid arthritis (RA) is an autoimmune disorder of unknown etiology. Morning stiffness, a characteristic feature of RA, shows a 24-hour rhythm. Cytokines, which are considered to play an important role in the pathogenesis of RA, also exhibit a 24-hour rhythm, with a peak in the early morning. These rhythms have been attributed to the endogenous hormone balance and changes in expression levels of clock-related genes. Chronotherapy based on the 24-hour rhythm of RA has been performed using glucocorticoids and disease-modifying antirheumatic drugs. In a previous study, it was reported that modified-release prednisone tablets were administered to patients with RA at night, which demonstrated that the severity of morning stiffness was markedly less than that in patients receiving the standard treatment. Methotrexate (MTX) is the most frequently used RA drug worldwide. In a basic study, cytokines and inflammatory responses in RA model animals showed 24-hour rhythms, based on which MTX was administered and exerted dosing time-dependent antirheumatic effects. Plasma C-reactive protein and cytokine levels also exhibit 24-hour rhythms in patients with RA, with peaks occurring in the early morning. MTX has been shown to markedly inhibit the exacerbation of arthritis in patients with RA when it is administered as inflammatory responses and tumor necrosis factor-α levels begin to increase. Tacrolimus (TAC) is an immunosuppressive agent that is administered to patients who undergo organ transplants. Since one of the mechanisms of action of TAC is the inhibition of inflammatory cytokine production, it is used as an RA therapeutic drug. When TAC was previously administered in the early light or early dark phase to RA model animals, the group treated in the early light phase had notably inhibited increase in arthritis scores compared with that in the early dark phase. The selection of an optimal dosing time associated with 24-hour rhythms in RA symptoms may lead to more effective and safer treatments for RA using glucocorticoids and disease-modifying antirheumatic drugs.

Keywords: methotrexate, steroid, circadian rhythm, cytokines

Chronobiology of rheumatoid arthritis

Rheumatoid arthritis (RA) is a systemic disease in which arthritis is the most important and common symptom. Extra-articular manifestations are often present when the disease is aggressive. Marked joint inflammation may lead to arthritic pain and the destruction of joints. Joint deformities and a loss of function ultimately occur with the progression of RA.1,2 Although many requirements must be met in order to establish a diagnosis of RA, morning stiffness is a characteristic feature and occurs in many patients. Pain, functional disability, and stiffness show 24-hour rhythms in many patients with RA, with a peak in the early morning.3,4 The 24-hour rhythms in pain and stiffness have been attributed to daily variations...
in local and systemic inflammatory responses. A previous study reported that plasma C-reactive protein (CRP) levels, an indicator of inflammatory responses, showed a 24-hour rhythm in patients with RA with a peak in the early morning and trough in the evening, which matched the 24-hour rhythms in pain and stiffness. Proinflammatory cytokines, such as tumor necrosis factor-α (TNF-α) and interleukin (IL)-6, are secreted from activated monocytes and macrophages and have been shown to increase the levels of CRP in hepatocytes. Clear 24-hour rhythms have been observed in the blood concentrations of these cytokines, with higher levels being reported in the early morning in patients with RA. However, no significant 24-hour rhythm in plasma IL-6 levels has been detected in healthy humans. Therefore, 24-hour rhythms in cytokines play central roles in the pathogenesis of RA.

Besides cytokines, the circadian rhythm and levels of melatonin (MLT) and glucocorticoids and a clock gene, Cryptochrome (Cry), may have effects on the 24-hour rhythm of RA symptoms. Arthritis scores and serum TNF-α concentrations were previously shown to be higher in Cry1−/−Cry2− mice than in the wild-type mice when both mice were inoculated anti-type II collagen monoclonal antibody in order to induce RA-like arthritis. Thus, Cry may play an important role in the induction of RA. MLT is known to enhance the expression of inflammatory cytokines, while glucocorticoids suppress the expression of cytokines such as IL-1, IL-6, and TNF-α. Both MLT and glucocorticoids have been shown to exhibit clear 24-hour rhythms. Previous studies showed that MLT levels peaked 2 hours earlier and the peak level of cortisol was lower in patients with RA than in healthy controls. Cytokine overexpression in patients with RA may be caused by a change in the balance between the circadian rhythms of MLT and corticosterone.

The mechanisms responsible for the 24-hour rhythms in RA symptoms have not yet been elucidated. However, the changes in concentrations of endogenous hormones and expression levels of clock-related genes compared with healthy controls appear to play important roles in the development of RA.

**Chronotherapy for RA**

Although RA symptoms exhibit 24-hour rhythms, therapy based on these rhythms (chronotherapy) has not yet been developed. Chronopharmacology and chronotherapies that have been examined in basic and clinical studies are discussed in the following sections.

### Glucocorticoids

Glucocorticoids have been used in RA therapy due to their anti-inflammatory activities against symptoms such as joint stiffness and joint pain. Cortisol is an endogenous glucocorticoid, which reaches the peak in the morning in humans. Steroids are generally administered in the morning in order to prevent disturbances in the circadian rhythms of endogenous glucocorticoids. Two previous studies attempted to clarify the dosing time dependency of glucocorticoids, which were administered in the morning or night according to the 24-hour rhythms of endogenous glucocorticoids and RA symptoms. The findings revealed that the duration of morning stiffness and blood IL-6 levels were markedly shorter and lower, respectively, in the night dosing group than in the morning dosing group. However, chronotherapy using glucocorticoids has not been widely performed in patients with RA. This may be explained by concerns about dosing in the middle of the night and abnormal secretion of endogenous glucocorticoids.

In recent years, chronotherapy using glucocorticoids has achieved important outcomes. A modified-release formulation of prednisone has been developed, which releases the agent 4 hours after its ingestion; therefore, patients with RA do not need to take the drug during the night (2–3 am) to get the anti-inflammatory effects induced by glucocorticoids. When patients with RA were randomly given a modified-release tablet at bedtime or an immediate-release prednisone tablet in the morning, relative changes in the duration of joint morning stiffness were significantly higher with the modified-release tablet than with the immediate-release tablet. Moreover, a large number of studies have demonstrated that the safety and effectiveness of these tablets in that chronotherapy do not reduce hypothalamic–pituitary–adrenal axis function or the secretion of endogenous glucocorticoids and are effective for the patients with RA who do not respond to immediate-release prednisone. Therefore, chronotherapy using modified-release prednisone tablets may be expected to become a useful RA therapy.

### Disease-modifying antirheumatic drugs

**Methotrexate**

Methotrexate (MTX) decreases the production of cytokines by suppressing the proliferation of lymphocytes and TNF-α transcriptional activity, inhibits joint inflammation, and induces a high American College of Rheumatology improvement response rate in patients with RA. Many factors must be considered prior to the administration of MTX in order to prevent the development of adverse effects such as myelosuppression and interstitial pneumonitis. Inflammatory responses
have been implicated in morning stiffness, a well-known characteristic of RA. However, MTX has not been examined using a dosing schedule based on the 24-hour rhythms.

Collagen-induced arthritis (CIA) represents a true autoimmune reaction against major joint components associated with class II major histocompatibility complex genes and pannus formation. The CIA model is similar to RA in terms of pathology, immunology, and genetics. In a basic study using rats with CIA, blood concentrations of CRP showed a significant 24-hour rhythm, with higher concentrations being observed in the late dark phase to the early light phase (Figure 1). A previous study administered MTX once daily at Zeitgeber time (ZT) 10 or ZT22 and found that the arthritis score was significantly lower in the ZT22 group than in the control and ZT10 groups in rats with CIA (Figure 1). On day 22, the inhibition rate of the arthritis score in the ZT22 group was approximately fivefold higher than that in the ZT10 group. Moreover, plasma TNF-α levels were found to be 3.03- to 5.39-fold higher in mice with CIA than in normal mice at all sampling times after the onset of RA. These levels showed a significant 24-hour rhythm with a peak at ZT2 and trough at ZT14. When MTX was intraperitoneally injected at ZT10 or ZT22, arthritis scores were significantly lower in the ZT22 group than in the control and ZT10 groups. On the other hand, the arthritis scores of the ZT10 group did not significantly differ from those of the control group for the entire study period in mice.

In our previous studies using CIA model, MTX dosing groups showed no significant adverse effects such as myelosuppression. MTX is an anticancer drug, the administration of which is often associated with adverse effects such as myelosuppression. However, the dose of MTX in RA therapy is 1/10 of that in cancer chemotherapy. Thus, MTX may reduce plasma TNF-α levels by suppressing transcriptional activity rather than suppressing lymphocyte proliferation.

In basic studies, 24-hour rhythms have been reported in inflammatory responses and cytokine levels after the onset of RA. Better antirheumatic effects may be obtained when MTX is administered at specific times in synchronization with circadian rhythms. Therefore, the selection of an optimal dosing time based on circadian rhythms in RA symptoms may lead to more effective MTX treatments for RA.

MTX is mainly administered three times a week (day 1: after breakfast and supper and day 2: after breakfast only) to Japanese patients with RA regardless of the total MTX dose per week. Based on our findings in animal studies and the circadian TNF-α rhythms of the patients with RA, we performed a prospective, single-arm study, in which we switched from the standard MTX schedule (MTX is administered three times a week) to a chronotherapy schedule.
(MTX is administered once a day before bedtime), and the
dose and number of doses per week were the same as the
standard MTX schedule for each Japanese patient with RA.  
Table 1 shows the time courses of tender and swollen joint
counts (28 joints), CRP levels, a global self-assessment of
disease activity, and Disease Activity Score (DAS) 28-CRP
as an indicator of disease activity in this study.  
Twenty-two patients with RA aged between 41 years and 78 years were
enrolled. Seventeen (77%) patients received chronotherapy
with MTX for the 3-month study period. Five patients
dropped out due to retraction of acceptance (n=1), out of
inclusion criteria just before study (n=1), lack of monitoring
data (n=1), and receive an operation without disease caused
by RA (n=2). The tender joint count decreased slightly after
chronotherapy. On the other hand, the swollen joint count
decreased markedly from 1.18 at the baseline (0 month) to
0.29 at 3 months. The CRP level continued to improve
throughout the 3-month study period and had improved by
64.2% after chronotherapy from that at the baseline. Visual
Analog Scale (VAS) was not significantly affected, despite
patients recognizing the change in the MTX administration
method. DAS28 was markedly improved after chronotherapy
from that at the baseline. The therapeutic effects of using
DAS28 are estimated by the European League Against Rheu-
matism (EULAR) response rates. The EULAR response
rates have been classified as follows: good responders are
patients displaying an improvement of >1.2 and a present
score of ≤2.7; moderate responders are patients displaying an
improvement of >0.6 and ≤1.2 and a present score of
≤4.1 or an improvement of >1.2 and a present score of
>4.1; and nonresponders are any patients displaying an
improvement of ≤0.6 or patients displaying an improvement
of >0.6 and ≤1.2 and a present score of >4.1.  
On the basis of the EULAR definitions of treatment responses according
to DAS28 at 3 months, seven (41.2%) patients achieved a
moderate response, and four (23.5%) attained clinical remis-
sion (Figure 2).  
Four out of five (80%) males and three out of
12 (25%) females achieved a moderate response, and
males obtained greater therapeutic effects than females.
Although most patients had mild leukopenia, the incidence
of leukopenia higher than grade 1 increased from 11.8% to
23.5% throughout the study. Moreover, no severe adverse
effects occurred in 17 patients. These findings demonstrated
that chronotherapy with MTX is safe and markedly improves
disease activity and the functional capacity of patients with
RA. We are now conducting a double-blind, randomized,
controlled trial of chronotherapy with MTX.

Chronotherapy with MTX is also being carefully exami-
ned in a clinical study, and selecting an optimal dosing time
in consideration of 24-hour rhythms in RA symptoms is
expected to lead to more effective MTX therapies for RA.

Tacrolimus
Tacrolimus (TAC) is used as prophylaxis for organ rejection
in patients undergoing transplants such as kidney, liver, or
heart. Its immunosuppressive effects inhibit the activation of
calcineurin, a phosphatase.  
These effects are exerted by
inhibiting the mRNA transcription of cytokine production
such as that of IL-2, which is required for the activation of
T-cells.  
TAC has been used in Japan as an RA therapeutic
drug because it inhibits the production of inflammatory
cytokines.

Table 1 Single-arm study of methotrexate chronotherapy in Japanese patients with RA

<table>
<thead>
<tr>
<th>Time after start of chronotherapy (month)</th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of tender joints</td>
<td>10.4±7.6</td>
<td>8.76±8.07</td>
<td>8.76±8.20</td>
<td>8.88±7.78</td>
</tr>
<tr>
<td>Number of swollen joints</td>
<td>1.18±1.51</td>
<td>0.18±0.73</td>
<td>0.41±1.46</td>
<td>0.29±0.99</td>
</tr>
<tr>
<td>CRP levels (mg/dL)</td>
<td>0.66±1.29</td>
<td>0.67±1.11</td>
<td>0.54±0.94</td>
<td>0.43±0.71</td>
</tr>
<tr>
<td>Patient’s global assessment of disease activity (VAS)</td>
<td>35.5±25.7</td>
<td>32.9±23.4</td>
<td>32.1±21.9</td>
<td>32.9±22.0</td>
</tr>
<tr>
<td>DAS28-CRP</td>
<td>3.83±0.62</td>
<td>3.37±1.12</td>
<td>3.33±1.08</td>
<td>3.31±1.04</td>
</tr>
</tbody>
</table>

Note: Each value represents the mean ± SD (n=17). Disease Activity Score (DAS) 28-CRP values were calculated as follows: DAS28 (CRP) = 0.56 × \(\sqrt{(TJC28)} + 0.28 \times \sqrt{(SJC28)} + 0.014 \times GH + 0.36 \times \ln(CRP+1) - 0.96 \) where TJC = tender joint count, SJC = swollen joint count, and GH = general health.

Abbreviations: CRP, C-reactive protein; RA, rheumatoid arthritis; DAS, Disease Activity Score; VAS, Visual Analog Scale.
The adverse effects of TAC depend on dosing times in rats, and previous studies have demonstrated that groups treated in the active phase were at higher risk of adverse effects than those treated in the inactive phase.35,36 The reason for this has been attributed to the maximum blood concentration (C_max) being markedly higher in the active phase than in the inactive phase in mice.37 Previous studies reported that the dosing time dependency of pharmacokinetics in addition to C_max and the area under the plasma concentration–time curve were greater in patients treated during the daytime than in those treated at night.38,39 These findings are consistent with dosing time-dependent changes in adverse effects.

TAC is administered once a day after dinner to patients with RA in order to prevent adverse effects. However, it has not yet been determined whether TAC needs to be administered once daily after dinner in order to achieve better antirheumatic effects in patients with RA. Figure 3 shows 24-hour rhythms in TNF-α levels before and after the onset of RA, and dosing time differences in the arthritis score for TAC in mice with CIA.40 Plasma TNF-α concentrations were found to be markedly higher in mice with CIA than in normal mice. Mice with CIA showed a significant 24-hour rhythm in TNF-α levels, with higher levels in the light phase and lower levels in the dark phase. This type of change was also observed for IL-6 and serum amyloid A (SAA). The 24-hour rhythms observed in these mice correspond to those in patients with RA. Since 24-hour rhythms in cytokines and SAA levels peaked during the light phase and were the lowest during the dark phase, TAC was administered at ZT2 or ZT14 to mice with CIA. Although increases in the arthritis score were not inhibited in the ZT14 group, the suppression of arthritis was markedly stronger in the ZT2 group than in the control group (Figure 3). The dosing time when TAC showed greater antirheumatic effects in mice was similar to that of MTX in our previous studies on animals,22,27 and both drugs had stronger inhibitory effects on arthritis during the early morning when cytokine levels increased. The selection of an optimal dosing time according to the 24-hour cycling of inflammatory cytokines may contribute to improvements in the RA therapeutic effects of TAC.

**Conclusion**

RA symptoms such as morning stiffness exhibit 24-hour rhythms. Chronotherapies using glucocorticoids and disease-modifying antirheumatic drugs that target these rhythms have been examined and achieved more beneficial outcomes than existing methods. We are currently performing basic and clinical studies to confirm the utility of chronotherapy involving various antirheumatic drugs, with the aim of developing safer and more effective RA therapies.

---

**Figure 3** The 24-hour rhythm in TNF-α levels and the dosing time dependency of TAC in mice with CIA.

**Notes:** Regarding TNF-α levels, each value represents the mean of five or six normal mice (closed triangle) and eleven to 16 mice with CIA (closed circle). A significant 24-hour rhythm in TNF-α levels was observed in mice with CIA. In order to estimate antirheumatic effects, TAC (4 mg/kg) was ip administered once a day at ZT2 (open diamonds) or ZT14 (closed diamonds) for 3 weeks (n=18, respectively). Saline was administered to the control group (closed circle; n=35). Each value represents the mean. The arthritis score was markedly lower in the ZT2 group than in the control and ZT14 groups. The mice were considered to have arthritis when significant changes in redness and/or swelling were noted in their digits or in other parts of their paws. Each inflamed toe counted as 1 point. Arthritis was graded on a scale of 0–5 for each wrist/ankle: 0= no changes; 1= slight erythema of the limbs; 2= minimal swelling; 3= moderate swelling and erythema of the limbs; 4= marked swelling and erythema of the limbs, 5= maximal swelling and redness of the limbs and ankylosis.

**Abbreviations:** CIA, collagen-induced arthritis; ip, intraperitoneally; TAC, tacrolimus; TNF-α, tumor necrosis factor-α; ZT, Zeitgeber time.
Disclosure

The authors report no conflicts of interest in this work.

References
